Yong-Chan Kim
Director/Miembro de la Junta en BAUDAX BIO, INC. .
Fortuna: 50 $ al 30/04/2024
Perfil
Yong-Chan Kim is the founder and current Chief Executive Officer & Director of TeraImmune, Inc., which is founded in 2016.
He is also currently an Independent Director at Baudax Bio, Inc. since 2023.
Dr. Kim holds a doctorate degree from Chungnam National University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 07/09/2023 | 4 520 ( 16.69% ) | 50 $ | 30/04/2024 |
Cargos activos de Yong-Chan Kim
| Empresas | Cargo | Inicio |
|---|---|---|
| BAUDAX BIO, INC. | Director/Miembro de la Junta | 03/07/2023 |
TeraImmune, Inc.
 TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Fundador | 01/01/2016 |
Formación de Yong-Chan Kim.
| Chungnam National University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BAUDAX BIO, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Health Technology |
- Bolsa de valores
- Insiders
- Yong-Chan Kim
